My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 2282

    1.

    Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

    Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M.

    Diabetes. 2001 Nov;50(11):2530-9.PMID: 11679431 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment.

    Tang-Christensen M, Vrang N, Larsen PJ.

    Diabetes. 1998 Apr;47(4):530-7.PMID: 9568683 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

    Donahey JC, van Dijk G, Woods SC, Seeley RJ.

    Brain Res. 1998 Jan 1;779(1-2):75-83.PMID: 9473596 [PubMed - indexed for MEDLINE]Related articles

    4.

    The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

    Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB.

    Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E745-52.PMID: 12217892 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.

    Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blázquez E.

    J Neurochem. 1996 Nov;67(5):1982-91.PMID: 8863504 [PubMed - indexed for MEDLINE]Related articles

    6.

    Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.

    Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E.

    Metabolism. 2000 Jun;49(6):709-17.PMID: 10877194 [PubMed - indexed for MEDLINE]Related articles

    7.

    The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

    Harder H, Nielsen L, Tu DT, Astrup A.

    Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation.

    Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD.

    Peptides. 1998;19(5):869-75.PMID: 9663452 [PubMed - indexed for MEDLINE]Related articles

    9.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

    Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB.

    Diabetes. 2007 Jan;56(1):8-15.PMID: 17192459 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    S 23521 decreases food intake and body weight gain in diet-induced obese rats.

    Claret M, Corominola H, Canals I, Nadal B, Chavanieu A, Pfeiffer B, Renard P, Gorostiaga C, Delagrange P, Grassy G, Gomis R.

    Obes Res. 2004 Oct;12(10):1596-603.PMID: 15536223 [PubMed - indexed for MEDLINE]Related articles

    12.

    The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

    Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M.

    Diabetologia. 2002 Feb;45(2):195-202.PMID: 11935150 [PubMed - indexed for MEDLINE]Related articles

    13.

    Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

    Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR.

    Endocrinology. 2005 Dec;146(12):5120-7. Epub 2005 Sep 8.PMID: 16150917 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

    Baggio LL, Huang Q, Brown TJ, Drucker DJ.

    Gastroenterology. 2004 Aug;127(2):546-58.PMID: 15300587 [PubMed - indexed for MEDLINE]Related articles

    15.

    Chronic intracerebroventricular administration of recombinant CART(42-89) peptide inhibits and causes weight loss in lean and obese Zucker (fa/fa) rats.

    Larsen PJ, Vrang N, Petersen PC, Kristensen P.

    Obes Res. 2000 Nov;8(8):590-6.PMID: 11156435 [PubMed - indexed for MEDLINE]Related articles

    16.

    Chronic central infusion of cocaine- and amphetamine-regulated transcript (CART 55-102): effects on body weight homeostasis in lean and high-fat-fed obese rats.

    Rohner-Jeanrenaud F, Craft LS, Bridwell J, Suter TM, Tinsley FC, Smiley DL, Burkhart DR, Statnick MA, Heiman ML, Ravussin E, Caro JF.

    Int J Obes Relat Metab Disord. 2002 Feb;26(2):143-9.PMID: 11850744 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats.

    Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, Van Heek M.

    Obes Res. 1998 Mar;6(2):147-56.PMID: 9545022 [PubMed - indexed for MEDLINE]Related articles

    18.

    The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

    Bock T, Pakkenberg B, Buschard K.

    APMIS. 2003 Dec;111(12):1117-24.PMID: 14678021 [PubMed - indexed for MEDLINE]Related articles

    19.

    Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

    Chelikani PK, Haver AC, Reidelberger RD.

    Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1695-706. Epub 2005 Feb 17.PMID: 15718384 [PubMed - indexed for MEDLINE]Related articles

    20.

    Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.

    Herling AW, Kilp S, Elvert R, Haschke G, Kramer W.

    Endocrinology. 2008 May;149(5):2557-66. Epub 2008 Feb 14.PMID: 18276749 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity